Praxis Precision Medicines Inc (PRAX)

NASD · Healthcare · Biotechnology · USA

Praxis Precision Medicines Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Praxis Precision Medicines is a biopharmaceutical company developing treatments for central nervous system disorders involving imbalanced neuronal signaling. The company uses two proprietary platforms, Cerebrum for small molecules and Solidus for antisense oligonucleotides, to create precision therapies targeting genetic neurological conditions, with multiple programs in clinical development including candidates for essential tremor and epilepsy.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Praxis Precision Medicines Inc stock.

Our verdict on PRAX

Not valued: We cannot value this company yet.

ETFs with the most weight in PRAX

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than PRAX in Biotechnology

129 more in this industry show a wider margin of safety.

Is PRAX undervalued or overvalued?

We do not publish a verdict on PRAX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of PRAX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.